Improved Sensitivity for Methotrexate Analysis Using Enzyme Multiplied Immunoassay Technique on the Siemens Viva-E Instrument

Borgman, Mark P.; Hiemer, Mary F.; Molinelli, Alejandro R.; Ritchie, James C.; Jortani, Saeed A.

doi:10.1097/ftd.0b013e31824b93a5

Cited by 20 publications

(14 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Fluorescence polarization immunoassay (FPIA) is the most widespread method for MTX determination [2]. However, FPIA is gradually disappearing and alternative assays [3,4] are gaining a market share. ARK™ MTX Immunoassay is a homogeneous immunoassay intended for the quantitative determination of MTX in human serum or plasma on automated clinical chemistry analyzers.…”

mentioning

confidence: 99%

Multicenter method evaluation of the ARK™ Methotrexate Immunoassay

Godefroid¹,

Meyer²,

Parsch³

et al. 2014

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

mentioning

confidence: 99%

Multicenter method evaluation of the ARK™ Methotrexate Immunoassay

Godefroid¹,

Meyer²,

Parsch³

et al. 2014

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

“…The linearity obtained in our study was higher compared to that obtained by Borgman et al . [ 3 ] on Siemens Viva-E instrument. However, it was much lower compared to the lower limit of 0.3 μMol/L claimed by the kit manufacturer.…”

mentioning

confidence: 99%

Establishing Syva Methotrexate Assay on Siemens Dimension RxL Analyzer: Experience in a Tertiary Cancer Care Laboratory

et al. 2017

View full text Add to dashboard Cite

“…Bouquie et al CMIA/FPIA but with application on TDx. They also observed an overestimation with EMIT as other authors 21,22 and discussed the role of the metabolite DAMPA. Since the imprecision of real samples was poorer than that of QC samples both in our and in published studies, the influence of endogen compounds and matrix effect may also be of importance despite the use of buffer in all assays.…”

Section: Discussionmentioning

confidence: 52%

“…18 poorer imprecisions than those obtained in previously published results with ARK on Cobas c502, that itself had poorer imprecisions than MTX-ARCHI. 17 Several authors compared assays for MTX determination vs TDX or mass spectrometry 10,16,17,[19][20][21] but no recent comparison was performed with HPLC method. The maximal and minimal systematic bias (-0.075 and 0.002 mM) were observed for MTX-TDX and MTX-ARCHI, respectively, below 0.1 mM in accord with bias criteria.…”

Section: Discussionmentioning

confidence: 99%

Comparison of four immunoassays to an HPLC method for the therapeutic drug monitoring of methotrexate: Influence of the hydroxylated metabolite levels and impact on clinical threshold

Descoeur

Dupuy

Bargnoux

et al. 2021

J Oncol Pharm Pract

View full text Add to dashboard Cite

Objectives Methotrexate requires therapeutic drug monitoring in oncology because of narrow therapeutic index, especially the metabolite 7-hydroxymethotrexate exhibits nephrotoxicity. The goal of this study was to evaluate different assays and their impact on clinical decisions. Methods Following routine measurement with Abbott TDxFLx® assay (MTX-TDX), 62 samples were analysed on Architect®i1000 (MTX-ARCHI), Xpand® (ARK/XPND), Indiko® (ARK/INDI), and HPLC (MTX-HPLC) as the reference method. The influence of 7-hydroxymethotrexate was explored on ARK reagent to document the cause of the observed bias. ROC curves were built to study the impact of the method on the discharge thresholds for the patients at three levels. Results Total imprecision was below 2.60% for the methotrexate-ARCHI and close to 10% for both ARK assays for plasma pools. The correlation coefficients were 0.93, 0.93, 0.89 and 0.95, the Bland–Altman difference plot revealed a bias of 0.075, 0.037, 0.049 and –0.002, and the number of results exceeding the TE criteria of 0.1 µM was 17 (27%), 13 (21%), 15 (24%) and 15 (24%) for MTX-TDX, ARK/INDI, ARK/XPND and MTX-ARCHI, respectively. Cross reactivity with 7-hydroxymethotrexate was between 1 and 9%. Overestimation of methotrexate concentration was between –4% and +32%. The most robust clinical level was found to be the highest level (0.2 µM) with ROC curves. Conclusions The authors found the best results for imprecision with chemiluminescent microparticle immunoassay method on methotrexate-ARCHI, with bias below to the RICOS recommendations and best correlation to the reference method. Impact on the threshold values for clinical decision need to be clearly exposed to clinicians.

show abstract

Improved Sensitivity for Methotrexate Analysis Using Enzyme Multiplied Immunoassay Technique on the Siemens Viva-E Instrument

Abstract: The described modifications have enhanced the sensitivity of the Syva EMIT assay for MTX measurements down to 0.05 μmole/L with acceptable precision that can be used in clinical practice for monitoring MTX therapy.

Cited by 20 publications

References 6 publications

Multicenter method evaluation of the ARK™ Methotrexate Immunoassay

Multicenter method evaluation of the ARK™ Methotrexate Immunoassay

Establishing Syva Methotrexate Assay on Siemens Dimension RxL Analyzer: Experience in a Tertiary Cancer Care Laboratory

Comparison of four immunoassays to an HPLC method for the therapeutic drug monitoring of methotrexate: Influence of the hydroxylated metabolite levels and impact on clinical threshold

Contact Info

Product

Resources

About